EXEL
Aquí creo que me he quedado solo...os dejo una PR que sacaron ayer para el tema de las conferencias de JPM que se celebran esta semana. Importante sobretodo por la información relacionada con plazos de sus estudios (muy detallado) y guidance 2020:
Exelixis Outlines Key Priorities and Anticipated Milestones for 2020-21, Announces Preliminary Fourth Quarter and Full Year 2019 Financial Results, and Provides 2020 Financial Guidance
https://ir.exelixis.com/news-releases/news-release-details/exelixis-outlines-key-priorities-and-anticipated-milestones-2020 Os dejo el resumen que me hecho, dentro la PR mucha más información.
Anticipated Cabozantinib Data Readouts in 2020:
CheckMate 9ER: (esto es fase 3) first half of 2020
COSMIC-311: (también fase 3) interim analysis first half of 2020
COSMIC-312: (otra fase 3) interim analysis second half of 2020
COSMIC-021: (fase 1b) "data from the metastatic castration-resistant prostate cancer (mCRPC)" en ASCO 2020 (febrero) y " non-small cell lung cancer (NSCLC) cohort when data have matured and at the appropriate time in 2020."
CheckMate 040: (fase 1/2) ASCO 2020 (febrero)
EXAMINER: (durante 2020 sin especificar...)
CANTATA: (fase 2) second half 2020
Additional Clinical Updates COSMIC-021, COSMIC-313, XL092 (estos se van más allá de 2020 así que tampoco hace falta tenerlos muy presentes...), y también va a empezar durante 2020 3 nuevos trials con ROCHE ("three phase 3 pivotal trials in advanced NSCLC, mCRPC and RCC")
Preliminary Fourth Quarter and Full Year 2019 Financial Results: Total revenues for 2019 are approximately $972 million for the full year and approximately $245 million for the fourth quarter 2019.
Cash and investments at year-end 2019 were approximately $1.4 billion.
2020 Financial Guidance: Total revenues are expected to be between $850 million and $900 million. (menos que 2019...motivo para que hoy baje)
Cash and investments at year end 2020 are expected to be in the $1.5 billion to $1.6 billion range. Importantly, this cash guidance does not include any potential new business development activity, which remains a key priority for Exelixis as we continue to build toward becoming a multi-product oncology company.
Los ER Q4: Final results will be released on Wednesday, February 26, after the close.